Should repeat ablation be viewed as strategic rather than salvage in refractory colorectal cancer liver metastasis?

Abstract

Recent evidence suggests that repeated application of radiofrequency ablation in patients with colorectal liver metastases who have progressed after systemic chemotherapy can provide survival outcomes comparable to those achieved with single ablation. This development challenges the traditional view that repeat ablation serves only as a last-line measure and instead supports its consideration as a strategic component of long-term disease control. Tumor size appears to be a primary determinant of local treatment effect, likely reflecting interactions among thermal energy distribution, vascular perfusion, and microenvironmental conditions that influence ablative margin integrity and recurrence risk. Beyond technical feasibility, the clinical value of staged ablation depends on its integration with systemic therapies and on timely intervention based on radiologic evidence of viable disease. Thoughtful selection of candidates, including assessment of intrahepatic tumor burden, functional hepatic reserve, and absence of uncontrolled extrahepatic spread, is essential for maximizing benefit. Repeat ablation may function as a bridging approach to resection or transplantation, a consolidation method to sustain remission after chemotherapy response, or a long-term strategy to maintain disease stability and quality of life. Continued prospective evaluation incorporating biological profiling and treatment sequencing is needed to define optimal use and fully realize its therapeutic potential.

Keywords: Colorectal liver metastases; Radiofrequency ablation; Repeat ablation; Locoregional therapy; Tumor microenvironment; Liver functional reserve; Hepatic tumor burden; Thermal injury mechanism; Long-term disease control; Treatment sequencing

Core Tip: Repeated radiofrequency ablation in patients with chemotherapy-refractory colorectal liver metastases can no longer be viewed solely as a salvage procedure. When guided by radiologic evidence of viable tumor enhancement and applied in a staged manner, repeat ablation may function as an active, strategy-driven modality for sustained disease control. By integrating tumor size, hepatic reserve, and absence of uncontrolled extrahepatic spread into candidate selection, repeat ablation can serve as a bridge to resection or transplantation, a consolidation method after partial systemic response, or a long-term approach to maintain quality of life.